Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.06 -0.65%

-$0.02 today

Market cap
$106.78M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.02M

Average 0.04M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$40.14M

FY 2025 · Annual

Investing Cash Flow

-$29.58M

FY 2025 · Annual

Financing Cash Flow

-$16.20M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(96.75M)(98.69M)(116.84M)(36.7M)(67.8M)
Depreciation & Amortization14.16M18.44M18.52M19.84M20.12M
Deferred Income Tax087K371K00
Stock-Based Compensation11.49M6.04M5.23M00
Change in Working Capital(12.3M)(5.72M)(3.99M)53.57M(41.72M)
Accounts Receivables(12.44M)(8.99M)2.25M(6.72M)(4.44M)
Inventory215K0000
Accounts Payables177K3.25M(6.31M)2.05M(3.27M)
Other Working Capital(252K)23K67K58.24M(34.01M)
Other Non-Cash Items(21.17M)(7.6M)71.95M(14.61M)49.26M
Operating Cash Flow(104.56M)(87.44M)(24.75M)22.1M(40.14M)
Capital Expenditures(18.56M)(2.44M)(1.07M)(2.58M)(2.37M)
Acquisitions (Net)00000
Purchases of Investments(143K)00(162.48M)(160.27M)
Sales of Investments15M126K063.69M134.24M
Other Investing Activities10.97M(456K)(14.44M)00
Investing Cash Flow7.28M(2.76M)(15.51M)(102.63M)(29.58M)
Debt Repayment(10.64M)(6.6M)24.56M18.17M(5.4M)
Common Stock Issued44.64M067.94M82.68M44.14K
Common Stock Repurchased0(569K)000
Dividends Paid00000
Other Financing Activities13.53M8.32M(9.64M)(11.04M)(10.85M)
Financing Cash Flow47.53M1.15M82.87M89.8M(16.2M)
Effect of Forex Changes(5.75M)(3.36M)884K(2.73M)6.24M
Net Change in Cash(55.51M)(92.42M)43.49M6.54M(79.67M)
Free Cash Flow(123.12M)(89.89M)(25.82M)19.52M(42.5M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$67.8M
+ D&A$20.1M
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$41.7M
+ Other Non-Cash$49.3M
= Operating Cash Flow-$40.1M
- Capex-$2.4M
= Free Cash Flow-$42.5M

Analysis

FY2025 free cash flow is -$42.5M. FCF conversion is 62.7% of net income. Operating cash flow was -$40.1M, with capex of -$2.4M. The largest bridge item is Other Non-Cash at $49.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 13, 2026
6-K6-K filingNov 12, 2026
SC 13D/ASC 13D/A filingNov 9, 2026
6-K6-K filingNov 9, 2026
6-K6-K filingOct 28, 2026

Does CLLS generate free cash flow?

Cellectis S.A. (CLLS) generated -$42.50M of free cash flow in fiscal 2025.

How much operating cash flow does CLLS produce?

Operating cash flow was -$40.14M, before capital expenditures of $2.37M.